Ukrainian pharmaceutical company Biopharma sells its business to the Germany’s STADA pharmaceutical company.
“Biopharma pharmaceutical business will become an integral part of STADA in Ukraine and has strong growth potential in the production of high-quality prescription and OTC drugs,” the German company noted.
The agreement provides for the acquisition of production facilities in Bila Tserkva (Kyiv Oblast). The merge of two companies will end in December 2019. The transaction amount is not indicated so far.ся.
By acquiring Biopharma business, STADA made one of the largest financial investments in the pharmaceutical sector of Ukraine.
“We see great potential in the Ukrainian market. With this acquisition, we will become an important player in the Ukrainian pharmaceutical market with a strong local production,” CEO of STADA, Peter Goldschmidt, said.
At the same time, the managing partner of Biopharma Konstantyn Efimenko, together with his partner Vasyl Khmelnytsky and financial investors, will focus on developing the company’s plasma processing business both in Ukraine and in international markets.
STADA’s business in Ukrainian will head the newly appointed CEO, Borys Labensky.
As The Journalist reported, Ukraine’s Cabinet changes composition of management and supervisory boards of all strategic enterprises.